This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.
SPECIFIC AIMS :
The specific aims of this pilot study are threefold: 1. To determine the acute effects of Methylcobalamin, as compared to placebo, on electroencephalogram (EEG changes.2. To determine the acute effects of Methylcobalamin, as compared to placebo, on neurocognitive performance.3. If the above goals were met, they would lead to a larger, more definitive trial. The larger trial would not only include a larger number of subjects, but would be designed to evaluate the duration of improvement in attention from a single dose as well whether improvements in cognition are observed over an extended period of time (e.g. several weeks). There exists a clear need for effective ADHD treatments that are safer and carry a reduced potential for drug abuse, and Methylcobalamin may prove to be an example of such a treatment. Preliminary evidence of effectiveness will increase the likelihood that Pharmaceutical or Nutriceutical manufacturers or government funding agencies will support full trials that are necessary to establish efficacy and safety.
Showing the most recent 10 out of 1085 publications
